Update regarding anemia in heart failure

Medic ro ◽  
2020 ◽  
Vol 6 (1) ◽  
pp. 8-13
Author(s):  
Roxana Marcela Sânpălean ◽  
Dorina Nastasia Petra

Heart failure (HF) is a burden for the healthcare system. The incidence will increase significantly due to the aging of po­pu­la­tion, which is associated with multiple comorbidities. Ane­mia and iron deficiency are common in patients with HF, their etiology being often multifactorial. The screening for anemia and iron deficiency is recommended as soon as pos­si­ble. There are often no targeted investigations, therefore a significant proportion of cases are underdiagnosed. The ma­nagement of patients may focus on identifying and correcting the cause. Anemia can occur due to nutritional deficiencies, infla­m­mation, renal failure, bone marrow dysfunction, neuro­hor­mo­nal activity, treatment and hemodilution. The appropriate the­ra­py for the patients with anemia and HF will contribute to the improvement of life quality. The only recommended iron product is ferric carboxymalose administered by in­tra­venous infusion. Under the appropriate treatment, the pa­tients showed an increase in effort tolerance, with an im­prove­ment in symptomatology and a lower number of hos­pi­ta­li­za­tion days. The management of these cases is handled by a multidisciplinary team consisting of a general prac­ti­tio­ner, a cardiologist and other specialists if the patient has other comorbidities. The role of the general practitioner is essential, as he can perform proper screening, prevention and management, developed by a multidisciplinary team, in order to reduce the cardiac morbidity and mortality.  

2019 ◽  
Vol 26 (4) ◽  
pp. 90-101 ◽  
Author(s):  
L. G. Voronkov ◽  
A.V. Liashenko ◽  
N. A. Tkach ◽  
L. P. Paraschenyuk

Regulatory, structural and functional disturbances of other organs and systems (kidney, hepar, vessels, skeletal muscles, brain etc) play the substantial role in CHF. These disturbances may be the conseguences of pre-existing states (hypertension, diabetes, hypo- or hyperthyreoidism etc) and from, other side, may reflect the progressive inherent changes in chronic heart failure (CHF) per se. In particular, currently relevant comorbidities in this syndrome are insulin resistance, diabetes mellitus, renal dysfunction, cognitive impairment, depression peripheral myopathy. Every of them demonstrate the close pathophysiologic interplay with CHF which results in clinical prognosis impairment and in decrease of life quality. Prevalence of renal dysfunction described in 39 % of patients with CHF in our research. Renal dysfunction connected with older age, high class of NYHA, diabetes mellitus, arterial hypertension, higher level of citrulline and uric acid in patients with CHF. Patients with iron deficiency characterized with high class of NYHA, low functionality and poor quality of life. In patients with iron deficiency noted high level of mortality and many critical clinical events. Prevalence of cognitive impairment described in 85 % of patients with CHF in our research. Cognitive dysfunction associated with older age, high class of NYHA, diabetes mellitus, arterial hypertension, bad life quality, high level of ceruloplasmin in patients with CHF. Taking to account above-mentioned comorbidities in quideline-recommended management of CHF and the use of additional therapeutic approaches targeted to its treatment represent the contemporary strategy of personalized treatment in this syndrome.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 4262-4262
Author(s):  
Manoj P Menon

Abstract Abstract 4262 Anemia in children under 5 years of age, defined by the World Health Organization as a hemoglobin (hb) level < 11g/L, is a global public health problem, affecting a significant percentage of the world's children. In addition to its contribution to childhood mortality, the role of anemia in cognitive impairment and educational attainment is also well recognized. According to the 2000-01 Demographic Health Survey (DHS), the prevalence of anemia in Uganda was 64% among children <5, similar to other countries in the region. A subsequent 2006 DHS noted that the prevalence of anemia had increased to 72% in Uganda. Although it is estimated that nearly half of all cases of anemia are due to iron deficiency, the causes of anemia, which disproportionately affect children and pregnant woman, are multifactorial and include nutritional deficiencies and parasitic infections. In endemic regions, the causative role of malaria is particularly important. The 2009 Uganda Malaria Indicator Survey (UMIS) is a nationally representative household survey which collects demographic data and measurements of hemoglobin and testing for malaria in addition to coverage estimates of malaria prevention and control activities. Hemoglobin measurements were collected via the HemoCue®, a point of use test. Malaria was detected both by peripheral blood smear and via the rapid diagnostic test, Paracheck-Pf®, which detects the presence of histidine rich protein 2 (HRP2). For this analysis, we utilized the results of the rapid diagnostic test, which is characterized by high sensitivity but lower specificity as the tests detect HRP2 which persists in the bloodstream after clearance of the parasite. The UMIS collected data on household assets. Using principal component analysis, a wealth index was created and households were stratified into wealth quintiles. We analyzed data on hemoglobin levels (adjusted for altitude) among children under 5 years. We assessed various risk factors and performed both univariate and bivariate analyses. Those variable which were significantly associated with anemia (p <0.05) were included in the multivariate analysis. The UMIS utilized a two-stage sample design; 4,421 households were randomly selected (response rate 97.5%) from 170 clusters. Half (51%) of the sampled children were female and over 80% were between 12 and 59 months. Of the 4,065 children under 5 in the sample, hemoglobin measurements were obtained on 3,878 children (95%). Of these, 61% of children <5 had a hb level less than 11 g/L; nearly 10% were severely anemic with a hb less than 8 g/L. On bivariate analysis, anemia was more common in children between 12–59 months (p =.001), living in rural areas (p=.001), in households in the poorest wealth quintiles (p<.001), in those households having problems in satisfying their food needs (p<.001) and among those with concomitant malaria infection (p <.001). The prevalence of anemia among children who tested negative for malaria was 45% (versus 77% among those who tested positive). Maternal education was inversely associated with anemia (p=.009). Neither household size nor distance to the nearest health facility were associated with anemia. The sex of the child was also not associated with anemia. Using a logistic regression model, only simultaneous malaria infection (p <.001) and living in poorer households (p <.001) were associated with anemia. While the prevalence of anemia has decreased in Uganda since the most recent national household survey in 2006, the burden of anemia remains unacceptably high. In this analysis, the detection of malaria via Paracheck-Pf® was significantly associated with anemia. Clearly, malaria prevention and effective treatment measures have expanded and as such have reduced the prevalence of malaria during this interim. While these control efforts are likely responsible for the observed downward trend in anemia prevalence, such public health endeavors are unlikely to be sufficient to reduce the burden of anemia. Although the UMIS did not collect data on nutritional deficiencies, previous studies have documented the high percentage of anemia attributed to iron deficiency globally. Therefore, prevention of anemia via iron supplementation and antihelmintics, in conjunction with malaria prevention and treatment strategies, will likely be necessary to halt the global toll of anemia. Disclosures: No relevant conflicts of interest to declare.


2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Prabhjot Singh Sidhu ◽  
Mark E. McAlindon ◽  
Kaye Drew ◽  
Reena Sidhu

Background and Aims. The role of capsule endoscopy (CE) in the <50 years of age patients with iron deficiency anaemia (IDA) remains unclear. We aim to assess its utility in this cohort.Methods. All patients referred for CE for recurrent IDA were included retrospectively. Patients were divided into Group 1 (<50 years) and Group 2 (≥50 years).Results. There were 971 patients with recurrent IDA and 28% belonged to Group 1. The mean age was 40 years in this group with a DY of 28% (n=76). Significant diagnoses included erosions and ulcers (26%;n=71), small bowel (SB) angioectasia (AE) (10%;n=27), SB tumours (3%;n=7), Crohn’s disease (3%;n=7), SB bowel strictures (1%;n=3), and SB varices (1%;n=2). On logistic regression, the presence of diabetes (P=0.02) and the use of warfarin (P=0.049) was associated with increased DY. The DY in Group 2 was 38% which was significantly higher than in Group 1 (P=0.02). While SB tumours were equally common in both groups, AE was commoner in Group 2 (P<0.001).Conclusion. A significant proportion of patients <50 years are referred for CE. Although the DY is lower compared to those ≥50 years, significant pathology is found in this age group. CE is advisable in patients <50 years old with recurrent IDA and negative bidirectional endoscopies.


2021 ◽  
Author(s):  
Nischit Baral ◽  
Nabin Raj Karki ◽  
Imran Akram ◽  
Ashiya Khan ◽  
Govinda Adhikari ◽  
...  

Introduction: The role of intravenous (IV) iron in chronic heart failure has been well studied, however, its role in acute heart failure (AHF) is less well-known. Including the recent AFFIRM-HF trial, we performed a systematic review and meta-analysis to highlight the role of IV iron in AHF with iron deficiency. Hypothesis: We hypothesized that IV iron does not change mortality or heart failure re-hospitalization rates in patients with AHF with iron deficiency. Methods: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) and cohort studies published from inception till June 30, 2021. We searched PubMed, MEDLINE, EMBASE (embase.com), and Cochrane database including only RCTs and Cohort studies. We also included one prospective and one retrospective Cohort studies and two RCTs in our meta-analysis. Eligible studies included adults with AHF, left ventricular ejection fraction less than 40%-50%, and able to receive IV iron therapy. Outcomes included re-hospitalization rates and overall mortality from 30 days to 52 weeks post randomization (in one RCT). We used random-effects model calculating Risk Ratio (RR) with 95% confidence interval (95% CI) using Review Manger 5.4 software. I2statistics was used to assess heterogeneity. Results: There were total 1561 participants in both groups (IV iron and placebo/control) of four studies. The controls were comparable in both cohort studies and both the RCTs were well matched. Our results showed re-hospitalization in 278 of 833 (33.37%) patients in the IV iron/exposure group and 337 of 728 (0.46%) patients in the placebo/control group. The pooled result showed that the risk of re-hospitalization was comparable across both groups (RR 0.85, 95%CI 0.62-1.17; I2=45%, P=0.14). However, subgroup analysis, including RCTs only showed that IV iron decreases re-hospitalization rate by 28% compared to placebo (RR 0.72, 95% CI: 0.64, 0.82, I2=0%, P<0.00001) but did not improve mortality when compared to placebo (RR 0.97, 95% CI: 0.73, 1.30, I2 =0%). Conclusions: IV iron showed significant improvement in re-hospitalization rate for AHF hospitalizations in iron deficient patients but did not improve overall mortality. We need larger RCTs to further validate its effect on mortality.


2017 ◽  
pp. 53-56
Author(s):  
Yu.P. Vdovychenko ◽  
◽  
E.N. Gopchuk ◽  

The article describes role of iron in the human body, the conditions associated with it’s deficiency, including in those who are pregnant and lactating women. The expediency of early diagnostic and appropriate treatment was noted. The role of enteral forms of iron, in the treatment of iron-deficiency conditions was described. Key words: obstetrics and gynecology, pregnancy, iron, iron deficiency, iron deficiency anemia, treatment, Heferol.


2017 ◽  
Vol 37 (6) ◽  
pp. 587-591 ◽  
Author(s):  
Aleix Cases Amenós ◽  
Raquel Ojeda López ◽  
José María Portolés Pérez

Kardiologiia ◽  
2020 ◽  
Vol 60 (1) ◽  
pp. 99-106
Author(s):  
V. Yu. Mareev ◽  
S. R. Gilyarevskiy ◽  
Yu. V. Mareev ◽  
Yu. L. Begrambekova ◽  
Yu. N. Belenkov ◽  
...  

.


2019 ◽  
Vol 1865 (7) ◽  
pp. 1925-1937 ◽  
Author(s):  
Hao Zhang ◽  
Pavel Zhabyeyev ◽  
Shaohua Wang ◽  
Gavin Y. Oudit

2006 ◽  
Vol 12 (6) ◽  
pp. S89
Author(s):  
Drosos Karageorgopoulos ◽  
Maria Anastasiou-Nana ◽  
Chara Matsouka ◽  
A. Leonti ◽  
Georgios Maroulidis ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document